Typhoid Vaccines
Oral live-attenuated, injectable polysaccharide, and conjugate vaccines for typhoid fever
This page catalogs 4 typhoid vaccine products spanning US-licensed oral and injectable options, a WHO-prequalified conjugate vaccine, and European formulations. The 2017 WHO prequalification of Typbar-TCV marked a milestone as the first typhoid conjugate vaccine recommended for routine use in endemic countries, offering longer-lasting protection than polysaccharide alternatives.
Last updated: April 2026.
Typhoid Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Vivotif | Typhoid vaccine live oral Ty21a | Emergent BioSolutions (PaxVax) | Live-attenuated oral | FDA Licensed, 1989 | Oral capsule series |
| Typhim Vi | Typhoid Vi polysaccharide vaccine | Sanofi Pasteur | Polysaccharide (Vi) | FDA Licensed, 1994 | Injectable Vi polysaccharide |
| Typbar-TCV | Typhoid conjugate vaccine (Vi-TT) | Bharat Biotech | Conjugate (Vi-tetanus toxoid) | WHO Prequalified, 2017 | First WHO-prequalified typhoid conjugate |
| Typherix | Typhoid Vi polysaccharide vaccine | GSK | Polysaccharide (Vi) | Licensed (non-US) | GSK Vi polysaccharide |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026), EMA Medicines database, and WHO Prequalified Vaccines list. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.